tbuckley/cabot-search huggingface dataset:
Abstract 4930: Ki-67 serves as a prognostic marker in early gastric cancer, but not in advanced gastric cancer
Authors: Won Sup Lee, Gyung Hyuck Ko, Se-Il Go, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Journal: Cancer Research (2016)

Abstract Ki-67 protein is a cellular marker for proliferation. The role of Ki-67 as a prognostic factor has not been established in gastric cancer. We previously demonstrated that CD44v plays an important role in EThe present study was performed toinvestigate the significance of Ki-67 expression as a biomarker in early gastric cancer (EGC), but not advanced gastric cancer (AGC). With the study, we foundthat there is correlation between CD44v and Ki67. Here, evaluated the clinical significance with tissue microarray of gastric cancer by performing immunohistochemical staining for Ki-67. Its clinical significance was analyzed with adjustment via the propensity score-matching. The median follow-up duration was 72 months (range: 3 - 120 months). Ki-67 positive group showed worse prognosis than Ki-67-negative group in EGC (5-YSR, 78.9% vs. 92.0%, p = 0.018), but not in advanced gastric cancer (AGC) (5-YSR, 58.5% vs. 59.2%, p = 0.951). Interestingly, in the patients with well-differentiated histology, prognosis for Ki-67-positive group was considerably worse than that for Ki-67-negative group (5-YSR, 67.0% vs. 94.4%, p = 0.012), but not in those with moderately differentiated (p = 0.504) and poorly-differentiated histology (p = 0.905). In this cohort, there was a strong correlation between the proportion of EGC and well-differentiated histology (r = 0.215, p = 0.002). Multivariate analysis also revealed that the positive-Ki- 67 expression serve as a poor prognostic factor in EGC (HR 4.346, 95% CI 1.397 - 13.515, p = 0.011), but not in all the patients (p = 0.171). With bootstrap resampling, we internally validated these results (p = 0.011). In conclusion, this study suggests that Ki-67 expression may be a good biomarker for prognosis prediction for EGC, but not for AGC. [This study was supported by a grant from the National R&amp;D Program for Cancer Control, Ministry for Health, Welfare &amp; Family Affairs, Republic of Korea.(0820050).] Citation Format: Won Sup Lee, Gyung Hyuck Ko, Se-Il Go, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha. Ki-67 serves as a prognostic marker in early gastric cancer, but not in advanced gastric cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4930.
A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM
Authors: Matthieu Duchmann, Thorsten Braun, Olivier Kosmider, Aline Renneville, Uwe Platzbecker, Lionel Ades, Marie Sebert, François Dreyfus, Sophie Park, Norbert Vey, Odile Beyne Rauzy, Stéphane De Botton, Jean-Baptiste Micol, Romain Guieze, Jean-Noel M. Bastie, Claude Preudhomme, Michaela Fontenay, Éric Solary, Pierre Fenaux, Raphaël Itzykson
Journal: Blood (2015)
Clinical Relevance of Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL)
Authors: Claire Schwab, Lucy Chilton, Amir Enshaie, Heather Morrison, Lisa Jones, Halima A Al-Shehhi, Amy Erhorn, Lisa J Russell, Ajay J Vora, Christopher D Mitchell, Sue M Richards, Nicholas Goulden, Sally Kinsey, Anthony V. Moorman, Christine J Harrison
Journal: Blood (2012)
Case 38-1967
Authors: Daniel D. Federman, Benjamin Castleman
Journal: New England Journal of Medicine (1967)

Presentation of Case* First admission. A seventy-two-year-old man was admitted to the hospital because of difficulty with urination.He had been well until two months previously, when there was the onset of frequency of urination, with nocturia, hematuria and dysuria. He had had no recent change in weight. There was no history of anorexia, fever, chills, pain in the chest, dyspnea or a cough.The patient did not appear acutely ill. The cervical veins were flat. A Grade 1 apical systolic murmur was heard. The lungs were clear. Moderate suprapubic tenderness was elicited, and the bladder was distended half way . . .
Genetic Determinants Of Disease Phenotype In Myelodysplastic Syndromes
Authors: Ilaria Ambaglio, Luca Malcovati, Elli Papaemmanuil, Anna Gallì, Matteo G Della Porta, Chiara Elena, Marta Ubezio, Elisa Bono, Matteo C Da Vià, Anna Cattaneo, Erica Travaglino, Rosangela Invernizzi, Peter J. Campbell, Mario Cazzola
Journal: Blood (2013)
Abstract 3147: Identification of developmental endothelial locus-1 on circulating extracellular vesicles as a novel biomarker for early breast cancer detection
Authors: Pyong-Gon P. Moon, Jeong-Eun Lee, Young-Eun Cho, Soo Jung Lee, Jin Hyang Jung, Yee Soo Chae, Han-Ik Bae, Young-Bum Kim, In-San Kim, Hoyong Park, Moon-Chang Baek
Journal: Cancer Research (2016)

Abstract Purpose: Currently, there are no molecular biomarkers for the early detection of breast cancer (BC). This study focused on identifying surface proteins found on circulating extracellular vesicles (EVs) for detecting early-stage BC. Experimental Design: Circulating EVs, isolated from the plasma of 10 patients with BC (stages I and II), and 5 healthy controls, were analyzed using LC-MS/MS. Developmental endothelial locus-1 protein (Del-1) was selected as a candidate biomarker. Two different enzyme-linked immunosorbent assays (ELISAs) were used to measure Del-1 in plasma samples from healthy controls (n = 81), patients with BC (n = 269), BC patients after surgical resection (n = 50), patients with benign breast tumors (n = 64), and patients with non-cancerous diseases (n = 98), in two cohorts. Results: Plasma Del-1 levels were significantly higher (P &amp;lt; 0.0001) in patients with BC than in all controls and returned to almost normal after tumor removal. The diagnostic accuracy of Del-1 was area under the curve (AUC), 0.961 [95% CI, 0.924-0.983], sensitivity of 94.70% and specificity of 86.36% in test cohort, and 0.968 [0.933-0.988], 92.31% and 86.62% in validation cohort for early-stage BC by one type of ELISA. Furthermore, Del-1 maintained diagnostic accuracy for patients with early-stage BC using the other type of ELISA (0.946 [0.905-0.972], 90.90%, and 77.14% in the test cohort; 0.943 [0.900-0.971], 89.23%, and 80.99% in the validation cohort). Conclusions: Del-1 on circulating EVs is a promising marker to improve identification of patients with early-stage BC and distinguish BC from benign breast tumors and non-cancerous diseases. Citation Format: Pyong-Gon P. Moon, Jeong-Eun Lee, Young-Eun Cho, Soo Jung Lee, Jin Hyang Jung, Yee Soo Chae, Han-Ik Bae, Young-Bum Kim, In-San Kim, Hoyong Park, Moon-Chang Baek. Identification of developmental endothelial locus-1 on circulating extracellular vesicles as a novel biomarker for early breast cancer detection. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3147.
Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Authors: Judith A. Paice, Russell Portenoy, Christina Lacchetti, Toby Campbell, Andrea Cheville, Marc Citron, Louis S. Constine, Andrea Cooper, Paul Glare, Frank Keefe, Lakshmi Koyyalagunta, Michael Levy, Christine Miaskowski, Shirley Otis-Green, Paul Sloan, Eduardo Bruera
Journal: Journal of Clinical Oncology (2016)

To provide evidence-based guidance on the optimum management of chronic pain in adult cancer survivors.An ASCO-convened expert panel conducted a systematic literature search of studies investigating chronic pain management in cancer survivors. Outcomes of interest included symptom relief, pain intensity, quality of life, functional outcomes, adverse events, misuse or diversion, and risk assessment or mitigation.A total of 63 studies met eligibility criteria and compose the evidentiary basis for the recommendations. Studies tended to be heterogeneous in terms of quality, size, and populations. Primary outcomes also varied across the studies, and in most cases, were not directly comparable because of different outcomes, measurements, and instruments used at different time points. Because of a paucity of high-quality evidence, many recommendations are based on expert consensus.Clinicians should screen for pain at each encounter. Recurrent disease, second malignancy, or late-onset treatment effects in any patient who reports new-onset pain should be evaluated, treated, and monitored. Clinicians should determine the need for other health professionals to provide comprehensive pain management care in patients with complex needs. Systemic nonopioid analgesics and adjuvant analgesics may be prescribed to relieve chronic pain and/or to improve function. Clinicians may prescribe a trial of opioids in carefully selected patients with cancer who do not respond to more conservative management and who continue to experience distress or functional impairment. Risks of adverse effects of opioids should be assessed. Clinicians should clearly understand terminology such as tolerance, dependence, abuse, and addiction as it relates to the use of opioids and should incorporate universal precautions to minimize abuse, addiction, and adverse consequences. Additional information is available at www.asco.org/chronic-pain-guideline and www.asco.org/guidelineswiki.
Sulindac and Erlotinib for Familial Adenomatous Polyposis—Reply
Authors: N. Jewel Samadder, Deborah W. Neklason, Randall W. Burt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution
Authors: Preetesh Jain, Hagop M. Kantarjian, Carlos Guillermo Romo, Alfonso Quintas-Cardama, Elias Jabbour, Marylou Cardenas-Turanzas, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Susan O'Brien, Jorge E. Cortes
Journal: Blood (2013)
Are There Clinical Implications of Racial Differences in HbA1c? Yes, to Not Consider Can Do Great Harm!
Authors: William H. Herman
Journal: Diabetes Care (2016)

Studies that have compared HbA1c levels by race have consistently demonstrated higher HbA1c levels in African Americans than in whites. These racial differences in HbA1c have not been explained by measured differences in glycemia, sociodemographic factors, clinical factors, access to care, or quality of care. Recently, a number of nonglycemic factors and several genetic polymorphisms that operate through nonglycemic mechanisms have been associated with HbA1c. Their distributions across racial groups and their impact on hemoglobin glycation need to be systematically explored. Thus, on the basis of evidence for racial differences in HbA1c, current clinical guidelines from the American Diabetes Association state: “It is important to take…race/ethnicity…into consideration when using the A1C to diagnose diabetes.” However, it is not clear from the guidelines how this recommendation might be actualized. So, the critical question is not whether racial differences in HbA1c exist between African Americans and whites; the important question is whether the observed differences in HbA1c level are clinically meaningful. Therefore, given the current controversy, we provide a Point-Counterpoint debate on this issue. In the point narrative below, Dr. Herman provides his argument that the failure to acknowledge that HbA1c might be a biased measure of average glycemia and an unwillingness to rigorously investigate this hypothesis will slow scientific progress and has the potential to do great harm. In the counterpoint narrative that follows Dr. Herman’s contribution, Dr. Selvin argues that there is no compelling evidence for racial differences in the validity of HbA1c as a measure of hyperglycemia and that race is a poor surrogate for differences in underlying causes of disease risk. —William T. Cefalu Editor in Chief, Diabetes Care
Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis
Authors: Rachael J Rigby, Jacquelyn Carr, Kelly Orgel, Stephanie L King, P Kay Lund, Christopher M Dekaney
Journal: Gut Microbes (2016)

Doxorubicin (DOXO) induces significant, but transient, increases in apoptosis in the stem cell zone of the jejunum, followed by mucosal damage involving a decrease in crypt proliferation, crypt number, and villus height. The gastrointestinal tract is home to a vast population of commensal bacteria and numerous studies have demonstrated a symbiotic relationship between intestinal bacteria and intestinal epithelial cells (IEC) in maintaining homeostatic functions of the intestine. However, whether enteric bacteria play a role in DOXO-induced damage is not well understood. We hypothesized that enteric bacteria are necessary for induction of apoptosis and damage associated with DOXO treatment. Conventionally raised (CONV) and germ free (GF) mice were given a single injection of DOXO, and intestinal tissue was collected at 6, 72, and 120 h after treatment and from no treatment (0 h) controls. Histology and morphometric analyses quantified apoptosis, mitosis, crypt depth, villus height, and crypt density. Immunostaining for muc2 and lysozyme evaluated Paneth cells, goblet cells or dual stained intermediate cells. DOXO administration induced significant increases in apoptosis in jejunal epithelium regardless of the presence of enteric bacteria; however, the resulting injury, as demonstrated by statistically significant changes in crypt depth, crypt number, and proliferative cell number, was dependent upon the presence of enteric bacteria. Furthermore, we observed expansion of Paneth and goblet cells and presence of intermediate cells only in CONV and not GF mice. These findings provide evidence that manipulation and/or depletion of the enteric microbiota may have clinical significance in limiting chemotherapy-induced mucositis.
Abstract 5265: Cloud-based somatic analysis platform for populations with paired tumor normal samples
Authors: Melanie Lou, Holly Beale
Journal: Cancer Research (2016)

Abstract Maverix Biomics introduces its cloud-based somatic analysis platform, a scientifically sound, end-to-end analysis solution that begins with quality control of fastq reads and leads to somatic variant calling, annotation and interactive analysis and has been validated using paired tumor normal cancer samples from the COSMIC cell line project (CLP). In addition to providing the ability to call somatic variants for cancer populations and features to explore characteristics within each of these populations, another strength of the Maverix Analytic Platform is the ability to compare multiple cancer populations - a limitation in other existing platforms. To support this functionality, our cloud-based platform has been optimized using the biological expectations of COSMIC CLP data and outfitted with interactive features within Maverix's Variant Explorer. Specifically, we maximized the sensitivity and minimized the percentage of unvalidated variants of two COSMIC cancer cell lines - small cell lung carcinoma and renal cell carcinoma. Then interactive analysis of this data using Maverix's Variant Explorer has identified somatic variants and affected genes specific to each cancer population and shared among both cancer populations. Our platform expedites data exploration and the ability to identify similarities and differences among cancer populations which is useful for tumor reclassification and for repurposing targeted therapies based on discovering similar genetic profiles across different types of cancer. Citation Format: Melanie Lou, Holly Beale. Cloud-based somatic analysis platform for populations with paired tumor normal samples. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5265.
Specific Gtpase Dynamin Isoforms Regulate Megakaryocyte Membrane Remodeling and The Formation Of Multivesicular Bodies and Microparticles
Authors: Yolande Chen, Arinola Awomolo, Jorie Aardema, Michael Hession, Francisco Javier Gonzalez, Hilary Christensen, Walter H. Kahr, Seth J. Corey
Journal: Blood (2013)
Endolymphatic Sac Tumor Showing Increased Activity on 68Ga DOTATATE PET/CT
Authors: Georgios Z. Papadakis, Corina Millo, Samira M. Sadowski, Ulas Bagci, Nicholas J. Patronas
Journal: Clinical Nuclear Medicine (2016)

Endolymphatic sac tumors (ELSTs) are rare tumors arising from the epithelium of the endolymphatic sac and duct that can be either sporadic or associated with von Hippel-Lindau (VHL) disease. We report a case of a VHL patient with histologically proven residual ELST who underwent Ga DOTATATE PET/CT showing increased activity (SUVmax, 6.29) by the ELST. The presented case of a VHL-associated ELST with increased Ga DOTATATE uptake indicates cell-surface expression of somatostatin receptors by this tumor, suggesting the potential application of somatostatin receptor imaging using Ga DOTA-conjugated peptides in the workup and management of these patients.
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)—Findings from the ACCENT dataset.
Authors: T. Andre, Q. Shi, G. A. Yothers, B. M. Bot, D. G. Haller, E. Van Cutsem, J. Cassidy, J. Benedetti, M. O'Connell, D. J. Sargent
Journal: Journal of Clinical Oncology (2010)

3616 Background: The ACCENT dataset contains pts treated on phase III AT trials (CT) from 1978- 2002. We examined OS outcomes over time, considering separately TTR and TRD, separately in stage II and III pts treated with 5FU/LV or 5FU/Lev. Methods: Data from 21 5-FU based AT CT for pts with stage II or III CC was analyzed using multivariate Cox models. Pts receiving surgery alone, 5-FU with oxaliplatin (oxal) or irinotecan (iri), or oral fluoropyrimidines were excluded. CT were prospectively defined as
Evaluating the Impact of the U.S. National Toxicology Program: A Case Study on Hexavalent Chromium
Authors: Yun Xie, Stephanie Holmgren, Danica M. K. Andrews, Mary S. Wolfe
Journal: Environmental Health Perspectives (2016)

Evaluating the impact of federally funded research with a broad, methodical, and objective approach is important to ensure that public funds advance the mission of federal agencies.
Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.
Authors: Alida C. Weidenaar, Hendrik J.M. de Jonge, Vaclav Fidler, Arja ter Elst, Tiny Meeuwsen, Jenny Douwes, Jessica C.A. Bouma, Karel Hählen, Willem A. Kamps, Evelina S. de Bont
Journal: Blood (2007)
Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center.
Authors: Jennifer Brooke Goldstein, Chad Tang, David S. Hong, Vivek Subbiah, Filip Janku, Kenneth R. Hess, Siqing Fu, Daniel D. Karp, Aung Naing, Apostolia Maria Tsimberidou, Jennifer J. Wheler, Ralph Zinner, Milind M. Javle, Gauri R. Varadhachary, Robert A. Wolff, David R. Fogelman, Funda Meric-Bernstam, Sarina Anne Piha-Paul
Journal: Journal of Clinical Oncology (2015)

320 Background: Pancreatic cancer is a disease that generally presents in advanced stage and is nearly fatal in all cases. In 2011, we reported our experience with pancreatic cancer patients enrolled on phase 1 clinical trials from 2004-2009. At the time, gemcitabine and erlotinib were the only US FDA approved drugs for pancreatic cancer. Median overall survival from presentation in the phase 1 clinic was 5 months. After an additional 5 years of progress, we queried the impact of novel cancer therapeutics, evolving molecular profiling, and targeted therapy on pancreatic cancer patient outcomes in the phase 1 setting. Methods: A retrospective review of advanced pancreatic adenocarcinoma patients from the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center, was conducted for patients treated from 1/2009 to 1/2014. Statistical analyses utilized the Kaplan-Meier method. Results: A total of 90 patients were identified in 50 trials reviewed. Median age was 62 years (40-84), 57% were male, and 40% had stage IV disease at presentation. Median documented PS was 1 (range 0-3). The median time from diagnosis to treatment on a phase I protocol was 15 months (0.2-119). Patients were treated with an average of 4 prior regimens prior to Phase 1 referral (0-10) with 8% having undergone &gt;5 treatments. The median overall survival from the first phase I treatment was 5.2 months, 95% CI = (4.4-6.3) and the 1 year overall survival from the first phase 1 treatment was 15% (9%- 25%). The median duration on regimen with best phase I response was 1.9 months (0.2-21.3). Of 88 evaluable, the best responses were PR in 1 patient and SD (&gt; 6 months) in 5 patients. Although 47 patients had biomarker profiling performed and 61 patients were treated with targeted therapy alone or in combination with cytotoxic therapy, only 6 patients (5 PD, 1 SD currently on protocol) were placed on trials based on biomarker testing results. Conclusions: Pancreatic cancer remains a difficult disease to treat with poor outcome. Referral to phase 1 occurs late in the disease course. Biomarker based therapies may be more successful with more stringent patient selection and when referred earlier or used prior to cytotoxic treatment.